Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 2/20 | 0.35 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19659421 | 0.89 | KLKB1 (0.36) | EGLN1KLKB1RIPK1ADORA2AADORA1 | |
| SCHEMBL30587613 | 0.88 | KLKB1 (0.38) | EGLN1KLKB1RIPK1ADORA2AADORA1 | |
| SCHEMBL29080895 | 0.86 | SSTR4 (0.37) | EGLN1KLKB1RIPK1ADORA2AADORA1 | |
| SCHEMBL18367236 | 0.85 | ADORA2A (0.40) | KLKB1RIPK1ADORA2AADORA1 | |
| SCHEMBL18367248 | 0.83 | SLC40A1 (0.42) | KLKB1RIPK1 | |
| SCHEMBL18367260 | 0.83 | SLC40A1 (0.42) | EGLN1KLKB1RIPK1 | |
| SCHEMBL18367281 | 0.81 | KLKB1 (0.40) | KLKB1RIPK1MYC | |
| SCHEMBL18367125 | 0.80 | LMNA (0.47) | KLKB1RIPK1 | |
| SCHEMBL22887714 | 0.77 | MEN1 (0.38) | EGLN1EGLN3TRPC5 | |
| SCHEMBL18367244 | 0.75 | KDM4C (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-112979660-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| CN-107849023-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-111269221-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | EGLN1 1135/4885KLKB1 2482/4885RIPK1 3064/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | EGLN1 1135/4885KLKB1 2482/4885RIPK1 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.